Cohort of Breast Cancer Patients. Identification of Genetic Determinants that Influence Resistance/Sensitivity and/or Toxicity to Adjuvant Cancer Treatment and Genetic Determinants for Developing Breast Cancer. FRESH-PEF73302-en Jacques ROPERS Cohort of Breast Cancer Patients. Identification of Genetic Determinants that Influence Resistance/Sensitivity and/or Toxicity to Adjuvant Cancer Treatment and Genetic Determinants for Developing Breast Cancer. SIGNAL FRESH-PEF73302-en 73302 FRESH-PEF73302 Hélène BLANCHE-KOCH Jean-François DELEUZE Xavier PIVOT Céline FAURE-MERCIER David COX INSTITUT NATIONAL DU CANCER (INCA) Epidemiology France Portal (PEF) INSTITUT NATIONAL DU CANCER (INCA) null Hélène;BLANCHE-KOCH Jean-François;DELEUZE Xavier;PIVOT Céline;FAURE-MERCIER David;COX genetic determinant breast cancer treatment Oncology Malignant neoplasms of breast Biological determinants: Genetic predisposition Healthcare system determinants: Use of care Biological determinants Healthcare system determinants The aims of this study are: — to identify determinants that influence resistance or sensitivity following adjuvant treatment with Herceptin®; — to identify determinants of cardiac toxicity following adjuvant treatment with Herceptin®; — to identify genetic determinants for developing different types of breast cancer: HER2+, triple negative, RH+; — to identify genetic determinants for developing breast cancer. null France Individuals Patients population Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) 1. Women over 18 years old. 2. Histologically confirmed, non-metastatic, operable breast adenocarcinoma. 3. HER2+ tumour: all patients undergoing adjuvant treatment with Trastuzumab. 4. Signed informed consent. Clinical data Participant-reported health data Biological data Paraclinical data (non-biological) : Imaging Implemented by independent operators Health event/morbidity Health event/mortality Health care consumption and services Other Through organizations (health services or institutions schools businesses etc.) [1000-10000[ individuals Converting or copying information into a structured record Observational Study Observational Study Cohort study 9,600 Unknown Restricted access Fully anonymised clinical data (no initials or order number; returned to correlation table; no date of birth; no reference to the healthcare centre or investigator that enrolled the patient) Requesting parties undertake to reference the study and its sponsor in all publications resulting from these data. may be made readily available to third parties: please contact those in charge of the study. Free access